This company listing is no longer active
Biotage Croissance future
Future contrôle des critères 2/6
Biotage devrait augmenter ses bénéfices et son chiffre d'affaires de 16.8% et de 2.9% par an respectivement. Le BPA devrait croître de de 16.6% par an. Le rendement des capitaux propres devrait être 6.8% dans 3 ans.
Informations clés
16.8%
Taux de croissance des bénéfices
16.57%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 19.4% |
| Taux de croissance des recettes | 2.9% |
| Rendement futur des capitaux propres | 6.85% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 11 Jul 2025 |
Mises à jour récentes de la croissance future
Recent updates
Biotage's (STO:BIOT) Dividend Will Be Increased To SEK1.65
The board of Biotage AB (publ) ( STO:BIOT ) has announced that it will be paying its dividend of SEK1.65 on the 2nd of...Biotage AB (publ)'s (STO:BIOT) Popularity With Investors Under Threat As Stock Sinks 26%
To the annoyance of some shareholders, Biotage AB (publ) ( STO:BIOT ) shares are down a considerable 26% in the last...Is Biotage (STO:BIOT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Product Launches And Focus On High-Growth Areas Will Strengthen Future Prospects
Expansion in manufacturing capacity and new product launches are likely to drive revenue growth and reduce backlog.Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?
Key Insights The projected fair value for Biotage is kr288 based on 2 Stage Free Cash Flow to Equity Current share...Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts
Biotage AB (publ) ( STO:BIOT ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings
Biotage AB (publ)'s ( STO:BIOT ) price-to-earnings (or "P/E") ratio of 58.6x might make it look like a strong sell...Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Biotage AB (publ) ( STO:BIOT ) shareholders, with its shares surging 12% to kr190 in...Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?
Key Insights Biotage's estimated fair value is kr290 based on 2 Stage Free Cash Flow to Equity Biotage's kr176 share...Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?
Biotage AB (publ) ( STO:BIOT ), is not the largest company out there, but it saw a decent share price growth of 19% on...Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Investors in Biotage AB (publ) ( STO:BIOT ) had a good week, as its shares rose 4.4% to close at kr166 following the...Biotage's (STO:BIOT) Dividend Will Be SEK1.60
Biotage AB (publ)'s ( STO:BIOT ) investors are due to receive a payment of SEK1.60 per share on 3rd of May. This means...Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Biotage AB (publ) ( STO:BIOT ) just released its yearly report and things are looking bullish. The company beat...Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Biotage AB (publ)'s ( STO:BIOT ) investors are due to receive a payment of SEK1.60 per share on 3rd of May. This makes...Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Biotage AB (publ) ( STO:BIOT ) has announced that it will pay a dividend of SEK1.60 per share on the 3rd of May. This...Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)
The market rallied behind Biotage AB (publ)'s ( STO:BIOT ) stock, leading do a rise in the share price after its recent...Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%
Despite an already strong run, Biotage AB (publ) ( STO:BIOT ) shares have been powering on, with a gain of 32% in the...Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Biotage AB (publ) ( STO:BIOT ) investors will be delighted, with the company turning in some strong numbers with its...Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)
With a price-to-earnings (or "P/E") ratio of 53.5x Biotage AB (publ) ( STO:BIOT ) may be sending very bearish signals...At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?
While Biotage AB (publ) ( STO:BIOT ) might not be the most widely known stock at the moment, it received a lot of...Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biotage fair value estimate is kr123 With kr109 share price...Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued
Key Insights Biotage's estimated fair value is kr203 based on 2 Stage Free Cash Flow to Equity Current share price of...Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Biotage AB (publ) ( STO:BIOT ) will increase its dividend from last year's comparable payment on the 5th of May to...These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?
Biotage AB (publ) ( STO:BIOT ), is not the largest company out there, but it saw a double-digit share price rise of...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2027 | 2,072 | 344 | 396 | 531 | 1 |
| 12/31/2026 | 1,890 | 275 | 327 | 447 | 1 |
| 12/31/2025 | 1,766 | 164 | 361 | 471 | 1 |
| 3/31/2025 | 1,961 | 255 | 188 | 348 | N/A |
| 12/31/2024 | 2,056 | 284 | 244 | 413 | N/A |
| 9/30/2024 | 2,117 | 257 | 243 | 406 | N/A |
| 6/30/2024 | 2,077 | 251 | 261 | 399 | N/A |
| 3/31/2024 | 1,981 | 236 | 268 | 381 | N/A |
| 12/31/2023 | 1,862 | 246 | 193 | 284 | N/A |
| 9/30/2023 | 1,603 | 189 | 148 | 229 | N/A |
| 6/30/2023 | 1,554 | 216 | 147 | 223 | N/A |
| 3/31/2023 | 1,541 | 240 | 220 | 295 | N/A |
| 12/31/2022 | 1,566 | 268 | 271 | 341 | N/A |
| 9/30/2022 | 1,524 | 240 | 285 | 346 | N/A |
| 6/30/2022 | 1,428 | 228 | 285 | 338 | N/A |
| 3/31/2022 | 1,337 | 216 | 290 | 342 | N/A |
| 12/31/2021 | 1,232 | 205 | 297 | 353 | N/A |
| 9/30/2021 | 1,188 | 203 | 273 | 336 | N/A |
| 6/30/2021 | 1,145 | 187 | 256 | 321 | N/A |
| 3/31/2021 | 1,096 | 174 | 222 | 286 | N/A |
| 12/31/2020 | 1,092 | 175 | 218 | 279 | N/A |
| 9/30/2020 | 1,083 | 149 | 213 | 268 | N/A |
| 6/30/2020 | 1,103 | 179 | 221 | 274 | N/A |
| 3/31/2020 | 1,131 | 201 | 211 | 260 | N/A |
| 12/31/2019 | 1,101 | 187 | 166 | 212 | N/A |
| 9/30/2019 | 1,047 | 196 | 145 | 187 | N/A |
| 6/30/2019 | 997 | 173 | 112 | 158 | N/A |
| 3/31/2019 | 951 | 170 | 94 | 139 | N/A |
| 12/31/2018 | 911 | 168 | N/A | 155 | N/A |
| 9/30/2018 | 865 | 175 | N/A | 170 | N/A |
| 6/30/2018 | 811 | 162 | N/A | 149 | N/A |
| 3/31/2018 | 771 | 148 | N/A | 168 | N/A |
| 12/31/2017 | 748 | 139 | N/A | 169 | N/A |
| 9/30/2017 | 738 | 122 | N/A | 145 | N/A |
| 6/30/2017 | 728 | 118 | N/A | 145 | N/A |
| 3/31/2017 | 694 | 105 | N/A | 131 | N/A |
| 12/31/2016 | 668 | 93 | N/A | 139 | N/A |
| 9/30/2016 | 657 | 96 | N/A | 130 | N/A |
| 6/30/2016 | 640 | 87 | N/A | 133 | N/A |
| 3/31/2016 | 625 | 78 | N/A | 133 | N/A |
| 12/31/2015 | 611 | 73 | N/A | 120 | N/A |
| 9/30/2015 | 580 | 83 | N/A | 116 | N/A |
| 6/30/2015 | 549 | 75 | N/A | 98 | N/A |
| 3/31/2015 | 521 | 75 | N/A | 94 | N/A |
| 12/31/2014 | 490 | 65 | N/A | 81 | N/A |
| 9/30/2014 | 474 | 53 | N/A | 72 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de BIOT ( 16.8% par an) est supérieure au taux d'épargne ( 1.5% ).
Bénéfices vs marché: Les bénéfices de BIOT ( 16.8% par an) devraient croître plus rapidement que le marché Swedish ( 8.6% par an).
Croissance élevée des bénéfices: Les bénéfices de BIOT devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de BIOT ( 2.9% par an) devrait croître plus lentement que le marché de Swedish ( -0.05% par an).
Croissance élevée des revenus: Le chiffre d'affaires de BIOT ( 2.9% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de BIOT devrait être faible dans 3 ans ( 6.8 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2025/07/23 23:59 |
| Cours de l'action en fin de journée | 2025/07/21 00:00 |
| Les revenus | 2025/03/31 |
| Revenus annuels | 2024/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Biotage AB (publ) est couverte par 3 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Samuel England | Berenberg |
| Odysseas Manesiotis | Berenberg |
| Marcus Bellander | Carnegie Investment Bank AB |